Lincoln Park Capital Fund
Lincoln Park Capital Fund is a Chicago-based asset management firm focused on opportunistic investing in public and private companies.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Lincoln Park Capital Fund Information
Geographic Data
Address: 440 N Wells Street Suite 410
City: Chicago
State: IL
Zip: 60654
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Lincolnpark Capital is an asset management firm that focuses on investing in real estate sector.
Contact Phone:
+13128229300
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2022 | Aquestive Therapeutics | Post-IPO Equity | 40M |
| 4/2014 | Phio Pharmaceuticals | Post-IPO Equity | 20M |
| 3/2021 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
| 7/2014 | Ocata Therapeutics | Post-IPO Equity | 30M |
| 9/2010 | Onstream Media | Post-IPO Equity | 900k |
| 4/2020 | Dare Bioscience | Post-IPO Equity | 15M |
| 10/2010 | Nuo Therapeutics | Post-IPO Equity | 13M |
| 2/2019 | rMark Bio | Seed Round | 1.5M |
| 1/2021 | Aileron Therapeutics | Post-IPO Secondary | 35.9M |
| 6/2022 | Evaxion Biotech | Post-IPO Equity | 40M |
| 1/2021 | Onconova Therapeutics | Post-IPO Equity | 0 |
| 6/2021 | Ocuphire Pharma | Post-IPO Equity | 15M |
| 6/2021 | Cyclerion Therapeutics | Post-IPO Equity | 0 |
| 12/2022 | Marker Therapeutics | Post-IPO Equity | 25M |
| 7/2019 | Leap Therapeutics | Post-IPO Equity | 21M |
| 11/2021 | Gridiron BioNutrients | Series B | 4M |
| 2/2014 | Plandai Biotechnology | Post-IPO Equity | 15.3M |
| 11/2022 | PaxMedica | Post-IPO Equity | 20M |
| 4/2014 | Elite Pharmaceuticals | Post-IPO Equity | 800k |
| 8/2022 | Kintara Therapeutics | Post-IPO Equity | 0 |
| 3/2022 | Biodesix | Post-IPO Equity | 0 |
| 5/2011 | Lightwave Logic | Post-IPO Equity | 20M |
| 1/2019 | Lightwave Logic | Post-IPO Equity | 25M |
| 8/2010 | Raptor Pharmaceuticals | Post-IPO Equity | 0 |
| 1/2018 | InVivo Therapeutics | Post-IPO Equity | 15.2M |
| 2/2013 | Nuo Therapeutics | Private Equity Round | 27.5M |
| 3/2020 | Emmaus Medical | Post-IPO Equity | 25M |
| 8/2022 | Kintara Therapeutics | Post-IPO Equity | 0 |
| 6/2022 | Evaxion Biotech | Post-IPO Equity | 0 |
| 4/2022 | Aquestive Therapeutics | Post-IPO Equity | 0 |
| 3/2022 | Biodesix | Post-IPO Equity | 0 |
| 11/2021 | Gridiron BioNutrients | Post-IPO Equity | 0 |
| 6/2021 | Ocuphire Pharma | Post-IPO Equity | 0 |
| 6/2021 | Cyclerion Therapeutics | Post-IPO Equity | 0 |
| 3/2021 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
| 1/2021 | Onconova Therapeutics | Post-IPO Equity | 0 |
| 1/2021 | Aileron Therapeutics | Post-IPO Secondary | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
